Navigation Links
Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
Date:3/16/2011

" Once primed, NitroMist's unique aerosol delivery system ensures consistent delivery with a propellant-driven, metered dose.*

Indications and Usage: NitroMist® is a nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

Important Safety Information: NitroMist® should not be used in patients who are using phosphodiesterase type 5 inhibitors, such as those used for the treatment of erectile dysfunction, which have been shown to potentiate the hypotensive effects of organic nitrates. NitroMist should not be used in patients with severe anemia, in patients with increased intracranial pressure, and in patients with a history of hypersensitivity to this or other nitrates or nitrites. Skin reactions consistent with hypersensitivity have been observed with organic nitrates. NitroMist should be used with caution if patients have low systolic blood pressure, are undergoing diuretic therapy, or are undergoing tissue-type plasminogen activator therapy.

Co-administration of aspirin and nitroglycerin has been reported to increase nitroglycerin levels and intravenous nitroglycerin reduces the anticoagulant effect of heparin, so activated partial thromboplastin times should be monitored. Oral administration of nitroglycerin increases bioavailability of ergotamine, so concomitant use of ergotamine and related drugs should be avoided.

Excessive use may lead to the development of tolerance.

Severe hypotension, particularly with upright posture, may occur even with small doses of nitroglycerin. Hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris. The benefits of NitroMist in patients with acute myocardial infarction or congestive heart failure have not been established. Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy.


'/>"/>
SOURCE Akrimax Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/nt9zlx/asia_pacific ) has ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... is a detailed type of imaging that customs a ... called a mammogram, is used to support in the ... An x-ray (radiograph) is a noninvasive medical test that ...
(Date:5/27/2015)... senior marketing associate with the animal health division of Eli Lilly and ... setting in Bangkok, Thailand , will be among the ... respect and dignity is the guiding star for me and my fellow ... LillyPad blog . Donatelli and Lilly colleagues from ... , France , Ukraine ...
(Date:5/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/9ffv95/2015_strategies ... "2015 Strategies in the European Coagulation Testing Market" ... comprehensive five-country report contains 500 pages, 120 tables, ... potential market entrants identify and evaluate business opportunities ... the next five years. The report ...
Breaking Medicine Technology:Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 3European Coagulation Testing Market Strategies 2015 2
... of Having a Venous ThromboEmbolism (VTE) is Reduced ... Treated With,Clexane(R) / Lovenox(R), BRIDGEWATER, N.J., April 20, ... PREVAIL (Prevention,of VTE after Acute Ischemic Stroke with ... The Lancet. The results of the trial showed,that ...
... Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused ... publication,of a research paper on two of ... paper appeared in the April issue,of the ... official Journal of the American Society of,Microbiology, ...
Cached Medicine Technology:The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 2The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 3The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 4The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 5The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 6Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4
(Date:5/27/2015)... 27, 2015 Khanna Vision Institute (KVI) announced ... portal focussed on keratoconus eye disease . Keratoconus is ... has its onset in the teenage years. It worsens over ... the front clear part of the eye is defective. It ... eye. It results in poor vision which cannot even be ...
(Date:5/27/2015)... New York (PRWEB) May 27, 2015 ... filed on behalf of individuals who allegedly ... related to the use of the antipsychotic drug ... litigation currently underway in Pennsylvania’s Philadelphia Court of ... is proceeding with its bellwether trial program, as ...
(Date:5/27/2015)... In today's healthcare landscape, where costs are ... challenging for doctors and hospitals to keep up with ... Austin-based HealthTronics, Inc. is offering a solution ... for clinically sophisticated applications. The company has now broadened ... Laser Ventures, Inc ., a mobile laser technology company ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ), ... enterprise organizations, announced today that SanMar Corporation successfully ... time, attendance and point tracking processes for over ... States. , Family-owned since 1971, Seattle-based SanMar ... private label, and mill brands. SanMar supplies apparel ...
(Date:5/27/2015)... AR (PRWEB) May 27, 2015 ... today announce a partnership to provide CMSA's Career ... community. This collaboration seeks to strengthen the case/care ... through CMSA’s CKP program. The mutually beneficial agreement ... identifying individual skills of talent in the healthcare, ...
Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3
... Mich. Scientists at the University of Michigan Comprehensive Cancer ... cancer stem cells, the small number of cells in a ... that breast cancer stem cells are regulated by a type ... These cells are drawn from the bone marrow to the ...
... Controlling blood pressure is not only a medical challenge, ... required to strictly adhere to a treatment plan that ... the ideas of wellness and health are also powerful ... This is especially true in the African American ...
... recent study by Merikangas and colleagues published in the ... American Academy of Child and Adolescent Psychiatry (JAACAP) ... with severely impairing mental disorders ever receive treatment for ... one third of adolescents with any mental disorder received ...
... Heart disease is the leading cause of death for ... disease is more than just one disease; there are many ... blood pressure, diabetes or other causes. In lipotoxic cardiomyopathy, for ... cells. Obesity and high-fat diets are major risk factors for ...
... According to the World Health Organisation (WHO), an estimated 322,000 ... fire and in many of these cases death could have ... intervention, when major burn patients have insufficient skin left to ... skin has literally to be grown from the patient,s own ...
... Reporter , MONDAY, Jan. 17 (HealthDay News) -- Few ... measure up, according to new research. Dermatologists evaluated ... from the sun,s ultraviolet rays and found only a ... can penetrate glass. "The vast majority of the ...
Cached Medicine News:Health News:U-M researchers find indirect path to attack breast cancer stem cells 2Health News:Storytelling may help control blood pressure in African-Americans 2Health News:Adolescents with severe mental disorders have never received treatment 2Health News:A different path to fat-related heart disease 2Health News:Nanotech medicine 2Health News:Nanotech medicine 3Health News:Nanotech medicine 4Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 2Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 3
... depurinated DNA and RNA from agarose gels ... 15 minutes ,Increases speed and efficiency of ... applied to gel ,Part of an integrated ... UV crosslinking in 2.5 hours, versus 29 ...
PosiBlot 30-30 Pads...
A blotter fit for use with the incredible new Criterion precast gel system, the Criterion blotter combines excellent blotting efficiency with the flexibility of the Trans-Blot system and the ease-of-...
... High resolution ,transfer of DNA and RNA ... downward capillary transfer allows for,alkaline buffer transfers ... in three hours. , Economical ... blotting paper. Convenient refill packs available., ...
Medicine Products: